Insulin analogs and cancer

Frontiers in Endocrinology

Volumn 3, Issue FEB, 2012, Pages

  Sciacca, Laura ^a   Le Moli, Rosario ^a   Vigneri, Riccardo ^a  

^a Garibaldi Nesima Hospital   (Italy)

Author keywords

Cancer; IGF 1 receptor; Insulin analogs; Insulin receptor; Insulin receptor isoforms

Indexed keywords

EID: 84871533494     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00021     Document Type: Review

References (64)

1. Avnet,S.,Sciacca,L.,Salerno,M.,Gancitano, G., Cassarino, M. F., Longhi, A., Zakikhani, M., Carboni, J. M., Gottardis, M., Giunti, A., Pollak, M., Vigneri, R., and Baldini, N. (2009). Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 69, 2443-2452.
2. Bahr, M., Kolter, T., Seipke, G., and Eckel, J. (1997). Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur. J. Pharmacol. 320, 259-265.
3. Becker, R. H. (2007). Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol. Ther. 9, 109-121.
4. Becker, R. H., and Frick, A. D. (2008). Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin. Pharmacokinet. 47, 7-20.
5. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., and Vigneri, R. (2009). Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623.
6. Berti, L., Kellerer, M., Bossenmaier, B., Seffer, E., Seipke, G., and Haring, H. U. (1998). The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison toAsp(B10) and regular insulin. Horm. Metab. Res. 30, 123-129.
7. Blanquart, C., Achi, J., and Issad, T. (2008). Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer. Biochem. Pharmacol. 76, 873-883.
8. Bolli, G. B., Di Marchi, R. D., Park, G. D., Pramming, S., and Koivisto, V. A. (1999). Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42, 1151-1167.
9. Brems, D. N., Alter, L. A., Beckage, M. J., Chance, R. E., Dimarchi, R. D., Green, L. K., Long, H. B., Pekar, A. H., Shields, J. E., and Frank, B. H. (1992). Altering the association properties of insulin by amino acid replacement. Protein Eng. 5, 527-533.
10. Ciaraldi, T. P., Carter, L., Seipke, G., Mudaliar, S., and Henry, R. R. (2001). Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J. Clin. Endocrinol. Metab. 86, 5838-5847.
11. Colhoun, H. M. (2009). Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755-1765.
12. Currie, C. J., Poole, C. D., and Gale, E. A. (2009). The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766-1777.
13. Dejgaard, A., Lynggaard, H., Rastam, J., and Krogsgaard Thomsen, M. (2009). No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52, 2507-2512.
14. Dideriksen, L. H., Jorgensen, J. L. N., and Drejer, K. (1992). Carcinogenic effect on female rats after 12 months administration of the insulin analog B10 Asp. Diabetes 41, 143A.
15. Drejer, K. (1992). The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab. Rev. 8, 259-285.
16. Ebeling, P., Tuominen, J. A., and Koivisto, V. A. (1996). Insulin analogues and carcinoma of the breast. Diabetologia 39, 124-125.
17. Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., and Vigneri, R. (1999). Insulin receptor isoform A, a newly recognized, highaffinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19, 3278-3288.
18. Furstenberger, G., and Senn, H. J. (2002). Insulin-like growth factors and cancer. Lancet Oncol. 3, 298-302.
19. Giorgino, F., Belfiore, A., Milazzo, G., Costantino, A., Maddux, B., Whittaker, J., Goldfine, I. D., and Vigneri, R. (1991). Overexpression of insulin receptors in fibroblast and ovary cells induces a ligandmediated transformed phenotype. Mol. Endocrinol. 5, 452-459.
20. Hansen, B. F., Danielsen, G. M., Drejer, K., Sorensen, A. R., Wiberg, F. C., Klein, H. H., and Lundemose, A. G. (1996). Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. 315(Pt 1), 271-279.
21. Heinemann, L., Weyer, C., Rauhaus, M., Heinrichs, S., and Heise, T. (1998). Variability of the metabolic effect of soluble insulin and the rapidacting insulin analog insulin aspart. Diabetes Care 21, 1910-1914.
22. Heise, T., Bott, S., Rave, K., Dressler, A., Rosskamp, R., and Heinemann, L. (2002). No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet. Med. 19, 490-495.
23. Hemkens,L. G.,Grouven,U.,Bender,R., Gunster,C.,Gutschmidt,S.,Selke,G. W., and Sawicki, P. T. (2009). Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732-1744.
24. Hennige, A. M., Strack, V., Metzinger, E., Seipke, G., Haring, H. U., and Kellerer, M. (2005). Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 48, 1891-1897.
25. Hirsch, I. B. (2005). Insulin analogues. N.Engl.J.Med.352, 174-183.
26. Holleman, F.,and Hoekstra, J. B. (1997). Insulin lispro. N. Engl. J. Med.337, 176-183.
27. Howey, D. C., Bowsher, R. R., Brunelle, R. L., and Woodworth, J. R. (1994). [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43, 396-402.
28. Ish-Shalom, D., Christoffersen, C. T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko, R. M., Naor, D., and De Meyts, P. (1997). Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 40(Suppl. 2), S25-S31.
29. Jensen, M., and De Meyts, P. (2009). Molecular mechanisms of differential intracellular signaling from the insulin receptor. Vitam. Horm. 80, 51-75.
30. Johnson, J. A., and Gale, E. A. (2010). Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59, 1129-1131.
31. Jonasson, J. M., Ljung, R., Talback, M., Haglund, B., Gudbjornsdottir, S., and Steineck, G. (2009). Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52, 1745-1754.
32. Kalli, K. R., Falowo, O. I., Bale, L. K., Zschunke, M. A., Roche, P. C., and Conover, C. A. (2002). Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143, 3259-3267.
33. Kurtzhals, P., Havelund, S., Jonassen, I., and Markussen, J. (1997). Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. 86, 1365-1368.
34. Kurtzhals, P., Schaffer, L., Sorensen, A., Kristensen, C., Jonassen, I., Schmid, C., and Trub, T. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49, 999-1005.
35. Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., and Bolli, G. B. (2000). Pharmacokinetics and pharmacody-namics of subcutaneous injection of long-acting human insulin analog glargine,NPHinsulin,andultralente human insulin and continuous sub-cutaneous infusion of insulin lispro. Diabetes 49, 2142-2148.
36. Leroith, D., and Yakar, S. (2007). Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 3, 302-310.
37. Leroith, D., and Roberts, C. T. Jr. (2003). The insulin-like growth factor system and cancer. Cancer Lett. 195, 127-137.
38. Liefvendahl, E., and Arnqvist, H. J. (2008). Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm. Metab. Res. 40, 369-374.
39. Mannucci, E., Monami, M., Balzi, D., Cresci, B., Pala, L., Melani, C., Lamanna, C., Bracali, I., Bigiarini, M., Barchielli, A., Marchionni, N., and Rotella, C. M. (2010). Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33, 1997-2003.
40. Markussen, J., Havelund, S., Kurtzhals, P.,Andersen,A. S., Halstrom, J., Hasselager, E., Larsen, U. D., Ribel, U., Schaffer, L., Vad, K., and Jonassen, I. (1996). Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281-288.
41. Mayer, D., Shukla, A., and Enzmann, H. (2008). Proliferative effects of insulin analogues on mammary epithelial cells. Arch. Physiol. Biochem. 114, 38-44.
42. Milazzo, G., Sciacca, L., Papa, V., Goldfine, I. D., and Vigneri, R. (1997). ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol. Carcinog. 18, 19-25.
43. Mosthaf, L., Grako, K., Dull, T. J., Coussens, L., Ullrich, A., and Mcclain, D. A. (1990). Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 9, 2409-2413.
44. Moxham, C. P., Duronio, V., and Jacobs, S. (1989). Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J. Biol. Chem. 264, 13238-13244.
45. Owens, D. R., Coates, P. A., Luzio, S. D., Tinbergen, J. P., and Kurzhals, R. (2000). Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23, 813-819.
46. Papa, V., Pezzino, V., Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., and Vigneri, R. (1990). Elevated insulin receptor content in human breast cancer. J. Clin. Invest. 86, 1503-1510.
47. Plank, J.,Wutte,A., Brunner, G., Siebenhofer, A., Semlitsch, B., Sommer, R., Hirschberger, S., and Pieber, T. R. (2002). A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25, 2053-2057.
48. Pocock, S. J., and Smeeth, L. (2009). Insulin glargine and malignancy: an unwarranted alarm. Lancet 374, 511-513.
49. Rakatzi, I., Ramrath, S., Ledwig, D., Dransfeld, O., Bartels, T., Seipke, G., and Eckel, J. (2003). A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52, 2227-2238.
50. Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., and Egger, M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363, 1346-1353.
51. Sciacca, L., Cassarino, M. F., Genua, M., Pandini, G., Le Moli, R., Squatrito, S., and Vigneri, R. (2010). Insulin analogues differently activate insulin receptor isoforms and postreceptor signalling. Diabetologia 53, 1743-1753.
52. Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., Goldfine, I. D., Vigneri, R., and Belfiore, A. (1999). Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18, 2471-2479.
53. Shukla, A., Grisouard, J., Ehemann, V., Hermani, A., Enzmann, H., and Mayer, D. (2009). Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr. Relat. Cancer 16, 429-441.
54. Simpson, K. L., and Spencer, C. M. (1999). Insulin aspart. Drugs 57, 759-65; discussion 766-767.
55. Slieker, L. J., Brooke, G. S., Dimarchi, R. D., Flora, D. B., Green, L. K., Hoffmann, J. A., Long, H. B., Fan, L., Shields, J. E., Sundell, K. L., Surface, P. L., and Chance, R. E. (1997). Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40(Suppl. 2), S54-S61.
56. Slieker, L. J., and Sundell, K. (1991). Modifications in the 28-29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding. Diabetes 40(Suppl. 1), 168A.
57. Smith, U., and Gale, E. A. (2009). Does diabetes therapy influence the risk of cancer? Diabetologia 52, 1699-1708.
58. Sommerfeld, M. R., Muller, G., Tschank, G., Seipke, G., Habermann, P., Kurrle, R., and Tennagels, N. (2010). In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5, e9540. doi:10.1371/journal.pone.0009540
59. Staiger, K., Hennige, A. M., Staiger, H., Haring, H. U., and Kellerer, M. (2007). Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm. Metab. Res. 39, 65-67.
60. Vajo, Z., Fawcett, J., and Duckworth, W. C. (2001). Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr. Rev. 22, 706-717.
61. Vella, V., Pandini, G., Sciacca, L., Mineo, R., Vigneri, R., Pezzino, V., and Belfiore, A. (2002). A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 87, 245-254.
62. Vigneri, P., Frasca, F., Sciacca, L., Frittitta, L., and Vigneri, R. (2006). Obesity and cancer. Nutr. Metab. Cardiovasc. Dis. 16, 1-7.
63. Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009). Diabetes and cancer. Endocr. Relat. Cancer 16, 1103-1123.
64. Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., and Werner, H. (2009). Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab. Res. Rev. 25, 41-49.